Difference between revisions of "Part:BBa I712004"
Line 40: | Line 40: | ||
<p>The experimental procedures used in this assay involved measuring fluorescence using Mean Fluorescence Intensity (M.F.I). Thus, the absolute values are arbitrary units, and cannot be directly compared to other systems. Our experiment, however, does reveal the relative strength of the CMV promoter device as compared to both of our well-characterized parts. </p> | <p>The experimental procedures used in this assay involved measuring fluorescence using Mean Fluorescence Intensity (M.F.I). Thus, the absolute values are arbitrary units, and cannot be directly compared to other systems. Our experiment, however, does reveal the relative strength of the CMV promoter device as compared to both of our well-characterized parts. </p> | ||
− | [[File:T--BostonU-- | + | [[File:T--BostonU--Bba_I712004_Validation_Part2.png|400px|thumb|left|As the figure demonstrates, the pCMV had approximately 2-fold greater fluorescence than the single operator site plasmid from the Gemini Library; however, the triple operator sire plasmid had about 3- to 4-fold greater fluorescence than the pCMV. The measurement units are arbitrary units of fluorescence.]] |
− | [[File:T--BostonU-- | + | [[File:T--BostonU--Bba_I712004_Validation_Part3.png|400px|thumb|center|As the figure demonstrates, the pCMV had approximately 2-fold greater fluorescence than the single operator site plasmid from the Gemini Library; however, the triple operator sire plasmid had about 3- to 4-fold greater fluorescence than the pCMV. The measurement units are arbitrary units of fluorescence.]] |
<!-- --> | <!-- --> |
Revision as of 01:28, 19 October 2016
CMV promoter
a constitutive expression promoter for use in mammalian cells. Ribosome binding site is included.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Functional Parameters
negative_regulators | -NA- |
positive_regulators | -NA- |
[http://2009.igem.org/Team:Heidelberg Heidelberg 2009 iGEM team] characterized this promoter in Part:BBa_K203100 as a first application for its newly developed units of promoter strength in mammalian cells, [http://2009.igem.org/Team:Heidelberg/Project_Measurement Relative Expression Units (REU)] and [http://2009.igem.org/Team:Heidelberg/Project_Measurement Relative Mammalian Promoter Units (RMPU)], where RMPU is directly proportional to PoPs and measured on a RNA level, whereas REU is measured on the protein level. We found CMV to have a strength of 5,52 REU (Standard Error of the Mean = 0,60) in [http://2009.igem.org/Team:Heidelberg/Eucaryopedia#HeLa HeLa cells], 6,57 (SEM = 0,91) in [http://2009.igem.org/Team:Heidelberg/Eucaryopedia#MCF-7 MCF-7 cells] and 9,96 (SEM = 1,52) in [http://2009.igem.org/Team:Heidelberg/Eucaryopedia#U2-OS U2-OS cells] cells (Fig 1). We furthermore found that CMV is not a truly constitutive promoter (but we [http://2009.igem.org/Team:Heidelberg/Project_Measurement#There_are_no_truly_constitutive_promoters_in_mammalian_cells argue] that no such promoter exists). In [http://2009.igem.org/Team:Heidelberg/Project_Measurement RMPU] (a mRNA-based unit directly proportional to PoPs), CMV has an activity of approx. 2.89 RPMU in HeLa cells,as measured by qRT-PCR (Fig. 3)
The [http://2016.igem.org/Team:BostonU/Description 2016 BostonU iGEM team] further characterized this CMV promoter part by cloning it upstream of a GFP, transiently transfecting in HEK293FT cells, and assaying expression through flow cytometry. The part was cloned upstream of a GFP gene in a pSB1C3 backbone and transiently transfected in HEK293FT cells using PEI-mediated transfection.
As part of the characterization, this part was also directly compared to parts BBa_K1875016, and BBa_K1875018, created by the BostonU team as part of their project, Gemini. Parts BBa_K1875016 and BBa_K1875018 contain minimal CMV promoters and “guide operators” homologous to a 20 base pair guide RNA on a guide RNA expression vector. These new parts were co-transfected into HEK293FT cells with a dCas9-VPR and the complementary guide RNA expressing vector and then assayed using flow cytometry. Fluorescence of the CMV promoter device was measured relative to these devices.
The CMV promoter device successfully expressed GFP in HEK293FT cells. Part BBa_K1875016, the operator containing only one binding site for the dCas9-VPR, expressed GFP at a level lower than the CMV promoter while part BBa_K1875018 , the operator containing three binding sites, had higher GFP expression.
The experimental procedures used in this assay involved measuring fluorescence using Mean Fluorescence Intensity (M.F.I). Thus, the absolute values are arbitrary units, and cannot be directly compared to other systems. Our experiment, however, does reveal the relative strength of the CMV promoter device as compared to both of our well-characterized parts.